Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates

Biolchi, Alessia; Angelis, Gabriella De; Moschioni, Monica; Tomei, Sara; Brunelli, Brunella; Giuliani, Maria; Bambini, Stefania; Borrow, Raymond; Claus, Heike; Gorla, Maria Cecília Outeiro; Hong, Eva; Lemos, Ana Paula Silva de; Lucidarme, Jay; Taha, Muhamed-Kheir; Vogel, Ulrich; Comanducci, Maurizio; Budroni, Sonia; Giuliani, Marzia M.; Rappuoli, Rino; Pizza, Mariagrazia; Boucher, Philip E.

doi:10.1016/j.vaccine.2020.09.050

Cited by 31 publications

(35 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The non-MenB isolates were previously described in detail [13]. Briefly, isolates belonged to two panels: one containing 227 isolates collected from England and Wales, Germany, and France (Euro-3 panel) between July 2007 and June 2008, and one consisting of 41 Brazilian isolates collected in the year 2012.…”

Section: Meningococcal Isolates: Euro-3 Panel and Brazilian Panelmentioning

confidence: 99%

“…The Brazilian panel consisted of five (12%) MenC, 16 (39%) MenW, and 20 (49%) MenY isolates. All isolates were characterized by multilocus sequence typing [13].…”

Section: Meningococcal Isolates: Euro-3 Panel and Brazilian Panelmentioning

confidence: 99%

“…The distribution of isolates in both panels according to 4CMenB antigen genotypes is presented in Fig. 1 [13].…”

Section: Meningococcal Isolates: Euro-3 Panel and Brazilian Panelmentioning

confidence: 99%

“…The hSBA assay was performed following an established protocol [14] with minor modifications, as previously described [13].…”

Section: Immunogenicity Assessmentmentioning

confidence: 99%

“…We previously reported that pooled sera from infants immunized with 4CMenB exhibit serum bactericidal activity against non-MenB strains, with 109 out of 147 strains (74.1%) of MenC, MenW, and MenY clinical isolates from Europe and Brazil being killed by sera collected from infants immunized with the 4CMenB vaccine [13]. Here, we describe the bactericidal activity of adolescent post-vaccination sera measured by serum bactericidal antibody assay using human complement (hSBA) against non-MenB strains selected from the same panels of European and Brazilian IMD isolates.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents

Biolchi¹,

Tomei²,

Brunelli³

et al. 2020

Infect Dis Ther

Self Cite

View full text Add to dashboard Cite

Introduction Invasive meningococcal disease (IMD) is an important public health concern. In developed countries, most IMD is caused by meningococcal serogroup B (MenB) and two protein-based MenB vaccines are currently available: the four-component vaccine 4CMenB (Bexsero, GSK) and the bivalent vaccine MenB-FHbp (Trumenba, Pfizer). Genes encoding the 4CMenB vaccine antigens are also present in strains belonging to other meningococcal serogroups. Methods To evaluate the potential of 4CMenB vaccination to protect adolescents against non-MenB IMD, we tested the bactericidal activity of sera from immunized adolescents on 147 (127 European and 20 Brazilian) non-MenB IMD isolates, with a serum bactericidal antibody assay using human complement (hSBA). Serum pools were prepared using samples from randomly selected participants in various clinical trials, pre- and post-vaccination: 12 adolescents who received two doses of 4CMenB 2 months apart, and 10 adolescents who received a single dose of a MenACWY conjugate vaccine (as positive control). Results 4CMenB pre-immune sera killed 7.5% of the 147 non-MenB isolates at hSBA titers ≥ 1:4. In total, 91 (61.9%) tested isolates were killed by post-dose 2 pooled sera at hSBA titers ≥ 1:4, corresponding to 44/80 (55.0%) MenC, 26/35 (74.3%) MenW, and 21/32 (65.6%) MenY isolates killed. Conclusion 4CMenB vaccination in adolescents induces bactericidal killing of non-MenB isolates, suggesting that mass vaccination could impact IMD due to serogroups other than MenB.

show abstract

Section: Meningococcal Isolates: Euro-3 Panel and Brazilian Panelmentioning

confidence: 99%

“…The Brazilian panel consisted of five (12%) MenC, 16 (39%) MenW, and 20 (49%) MenY isolates. All isolates were characterized by multilocus sequence typing [13].…”

Section: Meningococcal Isolates: Euro-3 Panel and Brazilian Panelmentioning

confidence: 99%

“…The distribution of isolates in both panels according to 4CMenB antigen genotypes is presented in Fig. 1 [13].…”

Section: Meningococcal Isolates: Euro-3 Panel and Brazilian Panelmentioning

confidence: 99%

“…The hSBA assay was performed following an established protocol [14] with minor modifications, as previously described [13].…”

Section: Immunogenicity Assessmentmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents

Biolchi¹,

Tomei²,

Brunelli³

et al. 2020

Infect Dis Ther

Self Cite

View full text Add to dashboard Cite

show abstract

Association of Use of a Meningococcus Group B Vaccine With Group B Invasive Meningococcal Disease Among Children in Portugal

Rodrigues

Marlow

Simões

et al. 2020

JAMA

View full text Add to dashboard Cite

IMPORTANCE A 4-component meningococcus group B vaccine (4CMenB) is the only vaccine in use to prevent group B invasive meningococcal disease in young children, but no matched controlled studies have evaluated it. OBJECTIVE To determine the association between receipt of 4CMenB and invasive group B meningococcal disease. DESIGN, SETTING, AND PARTICIPANTS Matched incidence density case-control study. Patients presenting from October 2014 to March 2019 were ascertained, with follow-up until death or discharge (last follow-up in June 2019) in 31 pediatric services in Portugal. Children and adolescent residents in Portugal with laboratory-confirmed invasive meningococcal disease were included. Controls, usually 2 per case, with unrelated conditions who were at the same hospital at the same time were matched for sex, age, and residence. EXPOSURES Immunization with 4CMenB, ascertained from the national database (2-4 doses are recommended, depending on age). MAIN OUTCOMES AND MEASURESThe primary outcome was group B invasive meningococcal disease in fully vaccinated cases compared with controls. The secondary outcomes were all serogroup invasive meningococcal disease in fully vaccinated cases compared with controls and group B and all serogroup invasive meningococcal disease in cases compared with controls who received at least 1 vaccine dose. RESULTSOf 117 patients with invasive meningococcal disease, 98 were eligible for inclusion and 82 had group B invasive meningococcal disease; 69 were old enough to have been fully vaccinated and considered protected. Among these 69 cases, the median (interquartile range) age was 24 (4.5-196) months, 42 were male, and the median (interquartile range) duration of hospitalization was 8 (0-86) days. Five of 69 cases (7.2%) and 33 of 142 controls (23.1%) were fully vaccinated (difference, −16.0% [95% CI, −26.3% to −5.7%]; odds ratio [OR], 0.21 [95% CI, 0.08-0.55]). For all serogroup invasive meningococcal disease, 6 of 85 cases (7.1%) and 39 of 175 controls (22.3%) were fully vaccinated (difference, −15.2% [95% CI, −24.3% to −6.1%]; OR, 0.22 [95% CI, 0.09-0.53]). For group B disease, 8 of 82 cases (9.8%) and 50 of 168 controls (29.8%) received at least 1 vaccine dose (difference, −20.0% [95% CI, −30.3% to −9.7%]; OR, 0.18 [95% CI, 0.08-0.44]) and for all serogroup invasive meningococcal disease, 11 of 98 cases (11.2%) and 61 of 201 controls (30.3%) received at least 1 vaccine dose (difference, −19.1% [95% CI, −28.8% to −9.5%]; OR, 0.23 [95% CI, 0.11-0.49]). CONCLUSIONS AND RELEVANCEDuring the first 5 years of vaccine availability in Portugal, vaccination with 4CMenB was less likely among children who developed invasive meningococcal disease compared with matched controls without invasive meningococcal disease. These findings may help inform the use of the 4CMenB vaccine in clinical practice.

show abstract

Genomic characterization of invasive meningococcal X isolates from Brazil, 1992–2022

Cassiolato

Camargo

Cecconi³

et al. 2023

Int Microbiol

View full text Add to dashboard Cite

Introduction Invasive meningococcal disease (IMD) is a major health problem. Given the post-COVID-19 pandemic scenario with the loosening of the non-pharmacological measures to control the virus transmission and considering the observed global reduction of meningococcal vaccination coverage, an increase in IMD cases can be expected. Methodology Using whole-genome sequencing, we characterized six Neisseria meningitidis serogroup X (MenX) isolates recovered from IMD cases in Brazil in the last 30 years. Results The predominance (66.6%, 4/6) of ST2888 presenting fHbp 160, NHBA 129, NadA 21, and PorA 19,15 was found on isolates. Two novel STs, 15458 and 15477, were described. Conclusion This study describes the circulation of MenX lineage ST2888 in Brazil, previously reported only in Europe. Continuous universal surveillance is crucial to implement prompt public health measures aiming to prevent and control non-vaccine preventable serogroup X IMD cases.

show abstract

Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates

Cited by 31 publications

References 45 publications

4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents

4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents

Association of Use of a Meningococcus Group B Vaccine With Group B Invasive Meningococcal Disease Among Children in Portugal

Genomic characterization of invasive meningococcal X isolates from Brazil, 1992–2022

Contact Info

Product

Resources

About